An accomplished pharmaceutical executive and strategic business leader, Dr. Gordon has extensive experience in the development of drugs from first in-human studies to approval and commercialization.
Dr. Gordon brings innovative approaches to the process, leveraging advantageous regulatory pathways and close collaborations with investigators, patient advocacy groups and key academic and government consortiums.
Prior to joining GCAR, Dr. Gordon served as Vice President, Oncology Department at AbbVie (a spin-off of Abbott), where he oversaw the development of AbbVie’s oncology projects. He played a critical role in the oncology business expansion, leading to AbbVie’s current position in Oncology. This includes the approval of venetoclax, several major acquisitions and other collaborations. Dr. Gordon was on the AbbVie-Genentech team that received the 2017 Prix Galien award for the Best Pharmaceutical Product.
Prior to AbbVie, Dr. Gordon was Chief Scientific Officer and Vice President of Clinical Affairs at Ovation Pharmaceuticals from 2001 to 2003.
Dr. Gordon entered the pharmaceutical industry in 1995, joining the G.D. Searle division of Monsanto, which eventually became part of Pharmacia.
What is Gary B. Gordon's net worth?
The estimated net worth of Gary B. Gordon is at least $294.03 thousand as of May 15th, 2026. Dr. Gordon owns 72,510 shares of TriSalus Life Sciences stock worth more than $294,028 as of June 22nd. This net worth approximation does not reflect any other investments that Dr. Gordon may own. Learn More about Gary B. Gordon's net worth.
How do I contact Gary B. Gordon?
Has Gary B. Gordon been buying or selling shares of TriSalus Life Sciences?
Within the last three months, Gary B. Gordon has bought $24,600.00 in TriSalus Life Sciences stock. Most recently, on Friday, May 15th, Gary B. Gordon bought 10,000 shares of TriSalus Life Sciences stock. The stock was acquired at an average cost of $2.46 per share, with a total value of $24,600.00. Following the completion of the transaction, the director now directly owns 72,510 shares of the company's stock, valued at $178,374.60. Learn More on Gary B. Gordon's trading history.
Who are TriSalus Life Sciences' active insiders?
Are insiders buying or selling shares of TriSalus Life Sciences?
During the last twelve months, TriSalus Life Sciences insiders bought shares 5 times. They purchased a total of 719,682 shares worth more than $1,804,176.38. During the last twelve months, insiders at the sold shares 11 times. They sold a total of 30,150 shares worth more than $119,849.35. The most recent insider tranaction occured on May, 15th when Director Mats Wahlstrom bought 60,000 shares worth more than $151,800.00. Insiders at TriSalus Life Sciences own 16.3% of the company.
Learn More about insider trades at TriSalus Life Sciences. Information on this page was last updated on 5/15/2026.
